Immunohistochemical analysis of expressions of hepatic cytochrome P450 in F344 rats following oral treatment with kava extract

Experimental and Toxicologic Pathology

Volumn 58, Issue 4, 2007, Pages 223-236

  Clayton, Natasha P ^a   Yoshizawa, Katsuhiko ^b,c   Kissling, Grace E ^a   Burka, Leo T ^a   Chan, Po Chuen ^a   Nyska, Abraham ^d  

^a NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^b ASTELLAS PHARMA INC   (Japan)

^c KANSAI MEDICAL UNIVERSITY   (Japan)

^d Biostatistics Branch National Institute of Environmental Health Sciences ^*  (Israel)

Author keywords

Cytochrome P450; F344 rat; Hepatocellular hypertrophy; Herb; Kava; Piper methysticum

Indexed keywords

CHOLESTEROL; CYTOCHROME P450 1A2; CYTOCHROME P450 2B1; CYTOCHROME P450 2D1; CYTOCHROME P450 2D6; CYTOCHROME P450 3A1; CYTOCHROME P450 ISOENZYME; GAMMA GLUTAMYLTRANSFERASE; KAVA EXTRACT;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DISEASE SEVERITY; ENZYME ACTIVATION; ENZYME ACTIVITY; FEEDING; FEMALE; GENE EXPRESSION; IMMUNOHISTOCHEMISTRY; LIVER HYPERTROPHY; LIVER TOXICITY; LIVER WEIGHT; MALE; NEUROTOXICITY; NONHUMAN; PIPER METHYSTICUM; PROTEIN EXPRESSION; RAT; SEQUENCE HOMOLOGY; SEX RATIO;

PIPER METHYSTICUM;

EID: 33845346818     PISSN: 09402993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.etp.2006.08.002     Document Type: Article

References (62)

1. Amacher D.E., Schomaker S.J., and Burkhardt J.E. The relationship among microsomal enzyme induction, liver weight and histological change in rat toxicology studies. Food Chem Toxicol 36 (1998) 831-839
2. Anke J., and Ramzan I. Kava hepatotoxicity: are we any closer to the truth?. Planta Med 70 (2004) 193-196
3. Anke J., and Ramzan I. Pharmacokinetic and pharmacodynamic drug interactions with Kava (Piper methysticum Forst. F.). J Ethnopharmacol 93 (2004) 153-160
4. Bilia A.R., Gallon S., and Vincieri F.F. Kava-kava and anxiety: growing knowledge about the efficacy and safety. Life Sci 70 (2002) 2581-2597
5. Boorman G.A., Haseman J.K., Waters M.D., Hardisty J.F., and Sills R.C. Quality review procedures necessary for rodent pathology databases and toxicogenomic studies: the National Toxicology Program experience. Toxicol Pathol 30 (2002) 88-92
6. Bressler R. Herb-drug interactions: interactions between kava and prescription medications. Geriatrics 60 (2005) 24-25
7. Campo J.V., McNabb J., Perel J.M., Mazariegos G.V., Hasegawa S.L., and Reyes J. Kava-induced fulminant hepatic failure. J Am Acad Child Adolesc Psychiatry 41 (2002) 631-632
8. Cattley R.C., and Popp J.A. Hepatocellular adaptive responses. In: Haschek W.M., Rousseaux C.G., and Wallig M.A. (Eds). Handbook of toxicologic pathology vol. 2 (2002), Academic Press, New York 202-203
9. Clouatre D.L. Kava kava: examining new reports of toxicity. Toxicol Lett 150 (2004) 85-96
10. Clough A.R., Bailie R.S., and Currie B. Liver function test abnormalities in users of aqueous kava extracts. J Toxicol Clin Toxicol 41 (2003) 821-829
11. Conover W.J. Practical nonparametric statistics. 1st ed (1971), John Wiley & Sons, New York
12. De Jager LS, Perfettl GA, Dlachenko GW. Analytical method development for the determination of kava in functional foods, 2004. FDA Science Forum Poster Abstract: A-64. 〈http://www.cfsan.fda.gov/~frf/forum04/A-64.htm〉
13. Dennehy C.E., Tsourounis C., and Miller A.E. Evaluation of herbal dietary supplements marketed on the internet for recreational use. Ann Pharmacother 39 (2005) 1634-1639
14. Dunn O.J. Multiple comparisons using rank sums. Technometrics 6 (1964) 241-252
15. Dunnett C.W. A multiple comparison procedure for comparing several treatments with a control. J Am Stat Assoc 50 (1955) 1096-1121
16. Ejiri N., Katayama K., and Doi K. Induction of cytochrome P450 isozymes by phenobarbital in pregnant rat and fetal livers and placenta. Exp Mol Pathol 78 (2005) 150-155
17. Food and Drug Administration (FDA). Letter to health care professionals about FDA seeking information on liver injury and Kava products, 19 December 2001. 〈http://www.cfsan.fda.gov/~dms/ds-ltr27.html〉
18. Food and Drug Administration (FDA). Kava-containing dietary supplements may be associates with severe liver injury. Consumer advisory, 25 March 2002. 〈http://www.cfsan.fda.gov/~dms/addskava.html〉
19. Gart J.J., Cu K.C., and Tarone R.E. Statistical issues in interpretation of chronic bioassay tests for carcinogenicity. J Natl Cancer Inst 62 (1979) 957-974
20. Giannini E.G., Testa R., and Savarino V. Liver enzyme alteration: a guide for clinicians. Can Med Assoc J 172 (2005) 367-379
21. Grossblatt N. Guide for the care and use of laboratory animals (1996), National Academy Press, Washington, DC
22. Gruenwald J. In-depth investigation into EU member states market restrictions on Kava products (prepared for Centre for the Development of Entreprise, Brussels, Belgium, March 2003). Kava report, 2003. 〈http://www.taxtyranny.ca/images/HTML/Health-Regulatory-History/Can ada/Articles/kavareport.pdf〉
23. Guengerich F.P. Common and uncommon cytochrome P450 reactions related to metabolism and chemical toxicity. Chem Res Toxicol 14 (2001) 611-650
24. Gurley B.J., Gardner S.F., Hubbard M.A., Williams D.K., Gentry W.B., Khan I.A., et al. In vivo effects of goldenseal, kava kava, black cohosh, and valerian on human cytochrome P450 1A2, 2D6, 2E1, and 3A4/5 phenotypes. Clin Pharmacol Ther 77 (2005) 415-426
25. He X., Lin L., and Lian L. Electrospray HPLC-MS in phytochemical analysis of kava (Pier methysticum) extract. Planta Med 63 (1997) 70-74
26. Hefner D. FDA studying claims kava may be harmful. J Natl Med Assoc 94 (2002) 285
27. Hsu S.Y., Lin M.H., Lin L.C., and Chou C.J. Toxicologic studies of dihydro-5, 6-dehydrokawain and 5,6-dehydrokawain. Planta Med 60 (1994) 88-90
28. Hu Z., Yang X., Ho P.C., Chan S.Y., Heng P.W., Chan E., et al. Herb-drug interactions: a literature reviews. Drugs 65 (2005) 1239-1282
29. Humberston C.I. Acute hepatitis induced by Kava Kava. Clin Toxicol 41 (2003) 109-113
30. Ingelman-Sundberg M. Human drug metabolising cytochrome P450 enzymes: properties and polymorphisms. Naunyn-Schmiedeberg's Arch Pharmacol 369 (2004) 89-104
31. Ingelman-Sundberg M. Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J 5 (2005) 6-13
32. Jamieson D.D., and Duffield P.H. Positive interaction of ethanol and kava resin in mice. Clin Exp Pharmacol Physiol 17 (1990) 509-514
33. Knight J.A. Liver function tests. J Infus Nurs 28 (2005) 108-117
34. Liu L.L., Gong L.K., Qi X.M., Cai Y., Wang H., Wu X.F., et al. Altered expression of cytochrome P450 and possible correlation with preneoplastic changes in early stage of rat hepatocarcinogenesis. Acta Pharmacol Sin 26 (2005) 737-744
35. Mathews J.D., Riley M.D., Fejo L., Munoz E., Milns N.R., Gardner I.D., et al. Effects of the heavy usage of kava on physical health: summary of a pilot survey in an aboriginal community. Med J Aust 148 (1988) 548-555
36. Mathews J.M., Etheridge A.S., and Black S.R. Inhibition of human cytochrome P450 activities by kava extract and kavalactones. Drug Metab Dispos 30 (2002) 1153-1157
37. Mathews J.M., Etheridge A.S., Valentine J.L., Black S.R., Coleman D.P., Patel P., et al. Pharmacokinetics and disposition of the kavalactone kawain: interaction with kava extract and kavalactones in vivo and in vitro. Drug Metab Dispos 33 (2005) 1555-1563
38. Mugford C.A., and Kedderis G.L. Sex-dependent metabolism of xenobiotics. Drug Metab Rev 30 (1998) 441-498
39. National Toxicity Program. 90 day gavage toxicity studies of KAVA KAVA EXTRACT in Fischer rats and B6C3F1 mice. (Study Identification: C20007-03/R2 & 04/M3; on going). Research Triangle Park, NC; 2005a.
40. National Toxicity Program. Testing status of agents at NTP (KAVA KAVA EXTRACT M990058). Research Triangle Park, NC; 2005b. 〈http://ntp.niehs.nih.gov/index.cfm?objectid=071516E-C6E1-7AAA-C90C 751E23D14C1B〉
41. Norton S.A., and Ruze P. Kava dermopathy. J Am Acad Dermatol 31 (1994) 89-97
42. Ohta M., and Toda G. Gamma-glutamyltranspeptidase (gamma-GT). Rinsho Byori 116 (2001) 62-71 (abstract in English, and article in Japanese)
43. Omiecinski C.J., Remmel R.P., and Hosagrahara V.P. Concise review of the cytochrome P450s and their roles in toxicology. Toxicol Sci 48 (1999) 151-156
44. Poolsup N., Po L., and Knight T. Pharmacogenetics and psychopharmacotherapy. J Clin Pharmacol Ther 25 (2002) 197-220
45. Rosalki S.B., Tarlow D., and Rau D. Plasma gamma-glutamyl transpeptidase elevation in patients receiving enzyme-inducing drugs. Lancet ii (1971) 376-377
46. Schmidt M. Analysis of hepatotoxic reactions listed by the BfArM (German Federal Institute for Drugs and Medical Devices), 2001. 〈http://www.emersonecologics.com/EmersonUpdate/EmersonUpdate-Vol0-K ava%20Report-Misc2002.pdf〉
47. Shirley E. A non-parametric equivalent of William's test for contrasting increasing dose levels of a treatment. Biometrics 33 (1977) 386-389
48. Singh Y.N. Kava: an overview. J Ethnopharmacol 37 (1992) 13-45
49. Singh Y.N. Potential for interaction of kava and St. John's wort with drugs. J Ethnopharmacol 100 (2005) 108-113
50. Singh Y.N., and Devkota A.K. Aqueous kava extracts do not affect liver function tests in rats. Planta Med 69 (2003) 496-499
51. Tani Y., Yamamoto H., Kamai Y., Maeda N., Hosokawa T., and Doi K. Hepatic CYP1A induction in 3-methylcholanthrene-treated transgenic rats with insufficient blood growth hormone. J Toxicol Pathol 14 (2001) 151-155
52. Teschke R., Gaus W., and Loew D. Kava extracts: safety and risks including rare hepatotoxicity. Phytomedicine 10 (2003) 440-446
53. Ulbricht C., Basch E., Boon H., Ernst E., Hammerness P., Sollars D., et al. Safety review of kava (Piper methysticum) by the natural standard research collaboration. Expert Opin Drug Saf 4 (2005) 779-794
54. Unger M., Holzgrable U., Jacobsen W., Cummings C., and Benet I.Z. Inhibition of cytochrome P450 3A4 by extracts and kavalactones of Piper methysticum (kava-kava). Planta Med 68 (2002) 1055-1058
55. Vandenberghe J. Hepatotoxicology: mechanisms of liver toxicity and methodological aspects. In: Niesink R.J.M., de Vries J., and Hollinger M.A. (Eds). Toxicology, principles and applications (1996), CRC Press, Boca Raton 703-723
56. Wanwimolruk S., Bhawan S., Coville P.F., and Chalcroft S.C. Genetic polymorphism of debrisoquine (CYP2D6) and proguanil (CYP2C19) in South Pacific Polynesian populations. Eur J Clin Pharmacol 54 (1998) 431-435
57. Whitton P.A., Lau A., Salisbury A., Whitehouse J., and Evans C.S. Kava lactones and the kava-kava controversy. Phytochemistry 64 (2003) 673-679
58. Williams D.A. A test for differences between treatment means when several dose levels are compared with a zero dose control. Biometrics 27 (1971) 103-117
59. Williams D.A. The comparison of several dose levels with a zero dose control. Biometrics 28 (1972) 519-531
60. Williams D.A. A note on Shirley's nonparametric test for comparing several dose levels with a zero-dose control. Biometrics 42 (1986) 183-186
61. Xu C., Li C.Y.T., and Kong A.N.T. Induction of Phase I, II, and III drug metabolism/transport by xenobiotics. Arch Pharm Res 28 (2005) 249-268
62. Zuber R., Anzenbacherova E., and Anzenbacher P. Cytochromes P450 and experimental models of drug metabolism. J Cell Mol Med 6 (2002) 189-198